KTTA News

Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, raised $24 million by offering 4.8 million units at $5, the low end of the range of $5 to $7. The company offered 1.9 million more units than anticipated. Each unit consists of one share of common stock and one warrant, exercisable at $6.25 (125% of the IPO...read more

Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, announced terms for its IPO on Friday. The Miami Beach, FL-based company plans to raise $17 million by offering 2.9 million shares and warrants at a price range of $5 to $7. The warrants are exercisable at 125% of the offering price. At the midpoint of the proposed range, Pasithea...read more

The IPO market revved back to life with nine IPOs raising $5.4 billion, joined by crypto exchange Coinbase’s direct listing. SPAC activity continued to decline, with just two raising $700 million. Pipeline activity held steady, with 10 IPOs, six SPACs, and one direct listing submitting initial filings. The first major direct listing on the Nasdaq, ...read more

Pasithea Therapeutics, a preclinical biotech researching drugs for psychiatric and neuro disorders, filed on Tuesday with the SEC to raise up to $20 million in an initial public offering. Pasithea is focused on the discovery and development of novel drugs for the treatment of psychiatric and neurological disorders. The company does not currently have a lead candidate in...read more